OR WAIT null SECS
Connor Iapoce is an assistant editor for HCPLive and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at firstname.lastname@example.org.
A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.
The use of ozanimod in both studies focusing on ulcerative colitis (UC) and those focusing on multiple sclerosis did not show a signficant increase in cardiovascular events, bradycardia, or cardiac conduction abnormalities, according to new findings.
In an interview with HCPLive at the 2022 Digestive Disease Week Annual Meeting, Miguel Regueiro, MD, Cleveland Clinic, discussed these new data and what they might represent for this patient population.
"I think for the practicing gastroenterologist, this lends comfort in terms of the safety findings in using ozanimod in patients, even who have ve had what we would consider mild cardiac events," Regueiro said. "It does not cause cardiac abnormalities and even in the patients that had cardiac abnormalities, the patients tolerated this quite well."
Regueiro went on to discuss the hierarchy of treatment for UC and Crohn's Disease. He noted that while there are no cross-comparisons of ozanimod and ustekinumab, each showed a statistically signficant higher benefit of remission and all primary outcomes, compared to placebo.
By looking at patient factors, clinicans can determine the severity of disease, risk factors for surgery, and other comorbidities to position the proper therapy for one of these patients.
"With all of that information, we are taking that into account and a shared decision way with our patients when we look to start these therapies," he said.
"Patient Identification and Treatment of Adult Patients with Moderately to Severely Active UC with ZEPOSIA (Ozanimod)," was presented at DDW 2022.